Clinical course, predictive factors and prognosis in patients with cirrhosis and type 1 hepatorenal syndrome treated with Terlipressin:: A retrospective analysis

被引:103
作者
Colle, I
Durand, F
Pessione, F
Rassiat, E
Bernuau, J
Barrière, E
Lebrec, D
Valla, DC
Moreau, R
机构
[1] Hop Beaujon, INSERM, U481, Lab Hemodynam Splanchn & Biol Vasc, Clichy, France
[2] Hop Beaujon, Serv Hepatol, Clichy, France
[3] Hop Beaujon, Unite Traitement Ambulatoire Malad Alcool, Clichy, France
关键词
cirrhosis; prognosis; terlipressin; type 1 hepatorenal syndrome;
D O I
10.1046/j.1440-1746.2002.02816.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Terlipressin has been proposed to treat renal failure in patients with type 1 hepatorenal syndrome (HRS). However, the predictive factors for improved renal function and survival are unknown in patients with type 1 HRS treated with terlipressin. The aim of the present retrospective study was to investigate the predictive factors and prognosis of patients with type 1 HRS treated with terlipressin. Methods: The clinical charts of 18 consecutive patients with cirrhosis and type 1 HRS treated with terlipressin were studied. The predictive factors for improved renal function and survival were identified using univariate analyses. Results: Improved renal function, indicated by a significant decrease in serum creatinine (61 +/- 4%), occurred in 11 (60%) patients. The only predictive factor for improved renal function was a Child-Pugh's score less than or equal to13 at the time of diagnosis of HRS (P = 0.02). Fifteen patients (83%) died at 45 days and the median survival was 24 days. Of the three patients who survived, two underwent successful orthotopic liver transplantation. Three predictive factors for survival were identified: absence of a precipitating factor for HRS (P = 0.012); improved renal function during terlipressin therapy (P = 0.05); and a dose of terlipressin greater than or equal to3 mg/day (P = 0.04). Conclusions: In patients with type 1 HRS treated with terlipressin, patients with improved renal function had less severe cirrhosis (Child-Pugh >10 but less than or equal to13) than patients without. The predictive factors for survival were the absence of a precipitating factor for HRS, the terlipressin-induced improvement in renal function and a dose of terlipressin of at least 3 mg/day. These findings suggest that a randomized controlled trial investigating the effect of terlipressin on survival in patients with type 1 HRS should be performed. (C) 2002 Blackwell Publishing Asia Pty Ltd.
引用
收藏
页码:882 / 888
页数:7
相关论文
共 19 条
[1]   Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide [J].
Angeli, P ;
Volpin, R ;
Gerunda, G ;
Craighero, R ;
Rone, P ;
Merenda, R ;
Amodio, P ;
Sticca, A ;
Caregaro, L ;
Maffei-Faccioli, A ;
Gatta, A .
HEPATOLOGY, 1999, 29 (06) :1690-1697
[2]   Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis [J].
Arroyo, V ;
Gines, P ;
Gerbes, AL ;
Dudley, FJ ;
Gentilini, P ;
Laffi, G ;
Reynolds, TB ;
RingLarsen, H ;
Scholmerich, J .
HEPATOLOGY, 1996, 23 (01) :164-176
[3]   Hepatorenal syndrome [J].
Bataller, R ;
Ginès, P ;
Guevara, M ;
Arroyo, V .
SEMINARS IN LIVER DISEASE, 1997, 17 (03) :233-247
[4]   Effect of terlipressine (Glypressine) on hepato-renal syndrome (HRS) in cirrhotic patients: Results of a pilot study. [J].
Bonnard, P ;
Bernard, B ;
Halimi, C ;
Mathurin, P ;
Demontis, R ;
di Martino, V ;
Henry-Biabaud, E ;
Mofredj, A ;
Poynard, T ;
Cadranel, JF .
GASTROENTEROLOGY, 1998, 114 (04) :A1214-A1214
[5]   REVERSAL OF HEPATORENAL-SYNDROME IN 4 PATIENTS BY PERORAL MISOPROSTOL (PROSTAGLANDIN-E1 ANALOG) AND ALBUMIN ADMINISTRATION [J].
FEVERY, J ;
VANCUTSEM, E ;
NEVENS, F ;
VANSTEENBERGEN, W ;
VERBERCKMOES, R ;
DEGROOTE, J .
JOURNAL OF HEPATOLOGY, 1990, 11 (02) :153-158
[6]   Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites [J].
Gadano, A ;
Moreau, R ;
Vachiery, F ;
Soupison, T ;
Yang, S ;
Cailmail, S ;
Sogni, P ;
Hadengue, A ;
Durand, F ;
Valla, D ;
Lebrec, D .
JOURNAL OF HEPATOLOGY, 1997, 26 (06) :1229-1234
[7]   INCIDENCE, PREDICTIVE FACTORS, AND PROGNOSIS OF THE HEPATORENAL-SYNDROME IN CIRRHOSIS WITH ASCITES [J].
GINES, A ;
ESCORSELL, A ;
GINES, P ;
SALO, J ;
JIMENEZ, W ;
INGLADA, L ;
NAVASA, M ;
CLARIA, J ;
RIMOLA, A ;
ARROYO, V ;
RODES, J .
GASTROENTEROLOGY, 1993, 105 (01) :229-236
[8]  
Gines P, 2001, HEPATOLOGY, V34, p186A
[9]   Spontaneous bacterial peritonitis [J].
Guarner, C ;
Soriano, G .
SEMINARS IN LIVER DISEASE, 1997, 17 (03) :203-217
[10]   Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion [J].
Guevara, M ;
Ginès, P ;
Fernández-Esparrach, G ;
Sort, P ;
Salmerón, JM ;
Jiménez, W ;
Arroyo, V ;
Rodés, J .
HEPATOLOGY, 1998, 27 (01) :35-41